N@N

Matt Miksic Maintained (ZBH) at Sell with Decreased Target to $125 on, May 31st, 2024

Matt Miksic of Barclays, Maintained "Zimmer Biomet Holdings, Inc." (ZBH) at Sell with Decreased Target from $130 to $125 on, May 31st, 2024.

Matt has made no other calls on ZBH in the last 4 months.

There are 10 other peers that have a rating on ZBH. Out of the 10 peers that are also analyzing ZBH, 7 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Mike Matson of "Needham" Reiterated at Hold on, Thursday, May 30th, 2024
• David Roman of "Goldman Sachs" Initiated at Hold and Held Target at $129 on, Thursday, May 30th, 2024
• Richard Newitter of "Truist Securities" Maintained at Hold with Decreased Target to $130 on, Friday, May 3rd, 2024
• Vijay Kumar of "Evercore ISI Group" Maintained at Hold with Increased Target to $130 on, Thursday, April 4th, 2024
• Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $140 on, Wednesday, April 3rd, 2024
• Caitlin Cronin of "Canaccord Genuity" Reiterated at Hold and Held Target at $130 on, Friday, February 23rd, 2024
• Robbie Marcus of "JP Morgan" Maintained at Hold with Increased Target to $125 on, Friday, February 9th, 2024

These are the ratings of the 3 analyists that currently disagree with Matt

---

• David Toung of "Argus Research" Upgraded from Hold to Strong Buy and Held Target at $150 on, Tuesday, May 21st, 2024
• Steven Lichtman of "Oppenheimer" Maintained at Buy with Increased Target to $155 on, Friday, May 3rd, 2024
• Shagun Singh of "RBC Capital" Reiterated at Buy and Held Target at $140 on, Friday, February 9th, 2024

Contributing Sources

---